Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPkeeper 301 Trial
Immuneering presented the design and methodology of its ongoing Phase 3 MAPkeeper 301 trial at the 2026 ESMO Congress.
Story updates
11:37:02 AM UTC
SquawkNews
Immuneering outlined the design of MAPKeeper 301, a global randomized Phase 3 trial testing atebimetinib+mGnP vs GnP in first-line metastatic PDAC, with overall survival as the primary endpoint. The study began dosing in June 2026 and is recruiting.Material DetailsContext by AI AnalystThis is a lat…